Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting.

ABSTRACT: Vascular endothelial growth factor A (VEGF-A) has therapeutic cardiovascular effects, but delivery challenges have impeded clinical development. We report the first clinical study of naked mRNA encoding VEGF-A (AZD8601) injected into the human heart. EPICCURE (ClinicalTrials.gov: NCT03370887) was a randomized, double-blind study of AZD8601 in patients with left ventricular ejection fraction (LVEF) 30%-50% who were undergoing elective coronary artery bypass surgery. Thirty epicardial injections of AZD8601 (total 3 mg) or placebo in citrate-buffered saline were targeted to ischemic but viable myocardial regions mapped using quantitative [¹⁵O]-water positron emission tomography. Seven patients received AZD8601 and four received placebo and were followed for 6 months. There were no 

SUBMITTER: Anttila V 

PROVIDER: S-EPMC10014220 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature